- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Somerset Today
By the People, for the People
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation
Institutional investor reduces stake in biotech company
Mar. 13, 2026 at 8:07am
Got story updates? Submit your updates here. ›
Capital International Investors, a major institutional investor, decreased its stake in Legend Biotech Corporation by 13% in the third quarter, selling 140,873 shares of the company's stock. Legend Biotech is a commercial-stage biopharmaceutical company focused on developing and commercializing chimeric antigen receptor T-cell (CAR-T) therapies for oncology.
Why it matters
The reduction in Capital International Investors' stake in Legend Biotech could signal a shift in sentiment around the company and its CAR-T therapy pipeline. As a major institutional investor, Capital International Investors' trading activity can influence the stock price and market perception of Legend Biotech.
The details
According to a recent SEC filing, Capital International Investors sold 140,873 shares of Legend Biotech Corporation in the third quarter, reducing its total stake in the company to 941,600 shares. This represents a 13% decrease in the investor's position. Legend Biotech is developing a CAR-T therapy called ciltacabtagene autoleucel (commercially marketed as Carvykti) for the treatment of relapsed or refractory multiple myeloma.
- Capital International Investors sold the shares in the third quarter of the year.
The players
Capital International Investors
A major institutional investor that decreased its stake in Legend Biotech Corporation.
Legend Biotech Corporation
A commercial-stage biopharmaceutical company focused on developing and commercializing chimeric antigen receptor T-cell (CAR-T) therapies for oncology.
The takeaway
The reduction in Capital International Investors' stake in Legend Biotech could signal a shift in sentiment around the company's CAR-T therapy pipeline, which bears watching as the market evaluates the commercial potential of Legend Biotech's lead asset, Carvykti, for relapsed or refractory multiple myeloma.
